Page 71 - Read Online

Karolak et al. J Cancer Metastasis Treat 2021;7:15 https://dx.doi.org/10.20517/2394-4722.2021.05 Page 15 of 16

23. Bracken AP, Brien GL, Verrijzer CP. Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation
and cancer. Genes Dev 2019;33:936-59. DOI PubMed PMC
24. Italiano A. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer. Pharmacol Ther 2016;165:26-31. DOI
PubMed
25. Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol 2017;29:375-81. DOI PubMed
26. Walters ZS, Villarejo-Balcells B, Olmos D, et al. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic
differentiation of rhabdomyosarcoma cells. Oncogene 2014;33:1148-57. DOI PubMed PMC
27. Ciarapica R, Russo G, Verginelli F, et al. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009;8:172-
5. DOI PubMed
28. Changchien YC, Tátrai P, Papp G, et al. Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste
homologue 2 (EZH2). J Transl Med 2012;10:216. DOI PubMed PMC
29. Yamaga K, Osaki M, Kidani K, Shomori K, Yoshida H, Ito H. High expression of enhancer of zeste homologue 2 indicates poor
prognosis in patients with soft tissue sarcomas. Mol Med Rep 2008;1:633-9. DOI PubMed
30. Yalçınkaya U, Uğraş N, Özgün G, et al. Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising
indicator of prognosis. Bosn J Basic Med Sci 2017;17:302-8. DOI PubMed PMC
31. Ramaglia M, D'Angelo V, Iannotta A, et al. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas.
Cancer Cell Int 2016;16:59. DOI PubMed PMC
32. Cho YJ, Kim SH, Kim EK, et al. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by
H3K27me3 in sarcoma. BMC Cancer 2018;18:158. DOI PubMed PMC
33. Ciarapica R, Pezzullo M, Verginelli F, et al. Ezh2 is up-regulated and correlates with Ki67 and CD31 expression in human pediatric
rhabdomyosarcoma. Published April 2010. DOI
34. . Wang, Q., Shapiro, K., Lu, Y., Shroyer, K. & Hwang, S. EZH2 expression in rhabdomyosarcoma: A potential biomarker and
therapeutic target. Modern Pathology 32 (2019).
35. Ciarapica R, Carcarino E, Adesso L, et al. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal
RMS. BMC Cancer 2014;14:139. DOI PubMed PMC
36. Oh TJ, Adhikari A, Mohamad T, Althobaiti A, Davie J. TBX3 represses TBX2 under the control of the PRC2 complex in skeletal
muscle and rhabdomyosarcoma. Oncogenesis 2019;8:27. DOI PubMed PMC
37. Ciarapica R, De Salvo M, Carcarino E, et al. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1
alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 2014;33:4173-84. DOI PubMed
38. Rota R, Carcarino E, De Salvo M, et al. 453: Enhancer of Zeste Homolog 2 (EZH2) modulation in either embryonal or PAX3-FOXO1
alveolar rhabdomyosarcoma shows different anti-tumoral effects. European Journal of Cancer 2014;50:S109-10. DOI
39. Alimova I, Birks DK, Harris PS, et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical
rhabdoid teratoid tumor cells. Neuro Oncol 2013;15:149-60. DOI PubMed PMC
40. Popovski D, et al. Targeted catalytic inhibition of EZH2 synergizes with low-dose panobinostat in malignant rhabdoid tumor. Neuro-
Oncology 19(2017). Published July 201741. DOI
41. Constantinidou, A. , et al. Epigenetic modulation in well differentiated (WD) and dedifferentiated (DD) liposarcoma (LPS): A novel
therapeutic approach. Annals of Oncology 27(2016). DOI
42. Gounder M, Schöffski P, Jones RL, et al. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an
international, open-label, phase 2 basket study. Lancet Oncol 2020;21:1423-32. DOI PubMed
43. Italiano A, Soria J, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and
advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 2018;19:649-59. DOI PubMed
44. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label,
single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433-42. DOI PubMed
45. Yap TA, Winter JN, Giulino-Roth L, et al. Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126
in Patients with Advanced Hematologic and Solid Tumors. Clin Cancer Res 2019;25:7331-9. DOI PubMed PMC
46. Jones BA, Varambally S, Arend RC. Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. Mol Cancer Ther
2018;17:591-602. DOI PubMed PMC
47. Schoffski P, Agulnik M, Stacchiotti S, et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial
sarcoma (NCT02601950). JCO 2017;35:11057.
48. Marchesi I, Sanna L, Fais M, Fiorentino FP, Giordano A, Bagella L. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A
novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. J Cell Physiol 2018;233:2360-5. DOI
PubMed
49. Wang C. Childhood rhabdomyosarcoma: recent advances and prospective views. J Dent Res 2012;91:341-50. DOI PubMed PMC
50. Romanelli A, Stazi G, Fioravanti R, et al. Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological
Evaluation in Cancer Cells. ACS Med Chem Lett 2020;11:977-83. DOI PubMed PMC
51. Dawson LE, D'Agostino L, Hakim AA, et al. Induction of Myogenic Differentiation Improves Chemosensitivity of Chemoresistant
Cells in Soft-Tissue Sarcoma Cell Lines. Sarcoma 2020;2020:8647981. DOI PubMed PMC
52. Kurmasheva RT, Sammons M, Favours E, et al. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the
Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2017;64:e26218. DOI PubMed PMC
53. Unland R, Borchardt C, Clemens D, Kool M, Dirksen U, Frühwald MC. Analysis of the antiproliferative effects of 3-deazaneoplanocin
A in combination with standard anticancer agents in rhabdoid tumor cell lines. Anticancer Drugs 2015;26:301-11. DOI PubMed